"There's all these things that need to happen in the body after you've eaten," Knudsen said. "GLP-1 is involved in that, and that's why it has both effects on different organs, and the brain ...

The compound she spent years investigating is GLP-1, which mimics a hormone in the brain that regulates appetite and makes ...

As Novo Nordisk's CFO, Karsten Munk Knudsen, said during the earnings call: We are serving almost two-thirds of the global GLP-1 market and then competition [is] sitting on the remaining one-third.

To do so, Novo Nordisk’s CFO, Karsten Munk Knudsen, says the company is now ... Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity ...